company background image
BEAM

Beam Therapeutics NasdaqGS:BEAM Stock Report

Last Price

US$46.82

Market Cap

US$3.2b

7D

5.7%

1Y

-31.2%

Updated

03 Dec, 2022

Data

Company Financials +
BEAM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

BEAM Stock Overview

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.

Beam Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Beam Therapeutics
Historical stock prices
Current Share PriceUS$46.82
52 Week HighUS$88.18
52 Week LowUS$27.77
Beta1.66
1 Month Change7.39%
3 Month Change-11.12%
1 Year Change-31.17%
3 Year Changen/a
5 Year Changen/a
Change since IPO149.71%

Recent News & Updates

Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Nov 08
Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Recent updates

Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Nov 08
Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts

Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

May 10
Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts

Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Mar 03
Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02
Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates

Could The Beam Therapeutics Inc. (NASDAQ:BEAM) Ownership Structure Tell Us Something Useful?

Feb 04
Could The Beam Therapeutics Inc. (NASDAQ:BEAM) Ownership Structure Tell Us Something Useful?

Shareholder Returns

BEAMUS BiotechsUS Market
7D5.7%4.2%1.5%
1Y-31.2%-7.4%-14.9%

Return vs Industry: BEAM underperformed the US Biotechs industry which returned -10.3% over the past year.

Return vs Market: BEAM underperformed the US Market which returned -16.1% over the past year.

Price Volatility

Is BEAM's price volatile compared to industry and market?
BEAM volatility
BEAM Average Weekly Movement11.6%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: BEAM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: BEAM's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2017507John Evanshttps://www.beamtx.com

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.

Beam Therapeutics Inc. Fundamentals Summary

How do Beam Therapeutics's earnings and revenue compare to its market cap?
BEAM fundamental statistics
Market CapUS$3.22b
Earnings (TTM)-US$315.45m
Revenue (TTM)US$91.95m

35.0x

P/S Ratio

-10.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BEAM income statement (TTM)
RevenueUS$91.95m
Cost of RevenueUS$232.13m
Gross Profit-US$140.18m
Other ExpensesUS$175.26m
Earnings-US$315.45m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-4.58
Gross Margin-152.45%
Net Profit Margin-343.06%
Debt/Equity Ratio0%

How did BEAM perform over the long term?

See historical performance and comparison